Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-010-1541-4PMID 21404110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.

  2010cited by this paper
• Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples.

  2010influential reference
• Vincristine: Can its therapeutic index be enhanced?

  2009cited by this paper
• Pharmacogenetics of Calcineurin Inhibitors in Renal Transplantation

  2009cited by this paper
• CYP450 pharmacogenetics for personalizing cancer therapy.

  2008cited by this paper
• Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated withcis-diamminedichloroplatinum(II)

  2008cited by this paper
• Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia

  2008cited by this paper
• Effect of race on vincristine‐associated neurotoxicity in pediatric acute lymphoblastic leukemia patients

  2008cited by this paper
• Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes

  2007cited by this paper
• Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population.

  2006cited by this paper
• SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5

  2006cited by this paper
• Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).

  2005cited by this paper
• Pharmacokinetics of vincristine sulfate in children

  2004cited by this paper
• Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions

  2004cited by this paper
• Increasing the dosage of vincristine

  2004cited by this paper
• Influence of the functional polymorphisms of the MDR-1 gene on vincristine pharmacokineties in childhood acute lymphoblastic leukemia.

  2003cited by this paper
• Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents

  2003cited by this paper
• Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia

  2002cited by this paper
• A new statistical method for haplotype reconstruction from population data.

  2001cited by this paper
• Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies

  2001influential reference
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.

  2001cited by this paper
• ENHANCED VINCRISTINE NEUROTOXICITY FROM DRUG INTERACTIONS: Case Report and Review of Literature

  2001cited by this paper
• Genetic polymorphism of cytochrome P450 3A5 in Chinese.

  2001cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

  2000cited by this paper
• Vincristine pharmacokinetics after repetitive dosing in children

  1999influential reference
• Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients

  1998cited by this paper
• Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL

  1995cited by this paper
• Pharmacokinetics and metabolism of vinca alkaloids.

  1993cited by this paper
• The pharmacokinetics of vincristine in man:

  1982cited by this paper

• Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

  2025cites this paper
• Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients

  2024influential citation
• Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice

  2023cites this paper
• Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

  2023cites this paper
• Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives

  2023cites this paper
• Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis

  2023cites this paper
• A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling.

  2023cites this paper
• Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response

  2022cites this paper
• Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts

  2022cites this paper
• A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children

  2022cites this paper
• Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis

  2022influential citation
• Variability in Human In Vitro Enzyme Kinetics.

  2021cites this paper
• Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor

  2021cites this paper
• Population pharmacokinetic model development and exposure–response analysis of vincristine in patients with malignant lymphoma

  2021cites this paper
• Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients

  2020cites this paper
• Centrosomal protein72 rs924607 and vincristine-induced neuropathy in pediatric acute lymphocytic leukemia: meta-analysis

  2020cites this paper
• Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cites this paper
• Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole

  2018cites this paper
• CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer

  2018cites this paper
• The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.

  2017cites this paper
• Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs

  2017influential citation
• Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use

  2016cites this paper
• Vincristine-induced peripheral neuropathy in pediatric cancer patients.

  2016cites this paper
• Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy

  2016cites this paper
• Genotypes Affecting the Pharmacokinetics of Anticancer Drugs

  2016cites this paper
• Toxicity of Cancer Therapy in Adolescents and Young Adults (AYAs).

  2015cites this paper
• Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

  2014cites this paper
• Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

  2014cites this paper
• Variability in human in vitro enzyme kinetics.

  2014cites this paper
• Design of a drug‐drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation

  2014cites this paper
• Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies

  2014cites this paper
• Optimizing drug development of anti‐cancer drugs in children using modelling and simulation

  2013cites this paper
• Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines

  2013cites this paper
• Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity

  2011cites this paper